紫杉醇持续滴注联合方案二线治疗难治性晚期食管鳞癌

Continuous Intravenous Infusion Paclitaxel Based Combination Regimen as Second Line Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

[目的]研究含紫杉醇(PTX)持续静脉滴注方案二线治疗晚期食管癌的疗效和毒性。[方法]26例晚期食管鳞癌患者应用含低剂量PTX持续静脉输注联合方案化疗:PTX20mg/m2,civ,16h,d1～3,d8～9;DDP3.75mg/m2,iv,d1～4,d8～11;5-Fu375mg/m2,civ,24h,d1～5,d8～12;叶酸60mg,po,d1～5,d8～12;21d为1个周期,至少应用2个周期。[结果]23例完成2个周期治疗者可评价疗效,CR1例,PR9例,SD10例,PD3例,有效率为43.5%,中位疾病进展时间(TTP)5.1个月。主要毒副反应为骨髓抑制和脱发,其他毒副反应较轻。[结论]低剂量PTX持续静脉输注联合方案治疗晚期食管鳞癌安全有效。

[Purpose] To investigate the response and toxicity of continuous intravenous infusion paclitaxel based combination regimen as second line chemotherapy for advanced esophageal squamous cell carcinoma（ESCC）.[Methods] Twenty-six with ESCC pathologically proved received continuous intravenous infusion paclitaxel（PTX） based combination regimen.The regimen schedule was：PTX 20mg/m2,civ,16h,d1-3,d8-9;DDP 3.75mg/m2,iv,d1-4,d8-11,5-Fu 375mg/m2,civ,24h,d1-5,d8-12;folic acid 60mg,po,d1-5,d8-12.Twenty-one days as a cycle,and each patient was treated at least two cycles.[Results] Response was evaluable in 23 cases with≥2 cycles,1 case in CR,9 cases in PR,10 cases in SD and 3 cases in PD,the overall response rate was 43.5%.The median TTP was 5.1 months.The main toxicities were myelosuppression and alopecia,and other toxicities were mild.[Conclusion] Continuous intravenous infusion paclitaxel based combination regimen for advanced ESCC is effective and tolerable.